source
- Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyoutSanofi has abandoned plans to seek approval for amlitelimab in atopic dermatitis, admitting that a drug once tipped as a potential blockbuster “would not represent a meaningful improvement” to exis…Fierce Biotech · 5d ago↗ source
- Scribe secures $129M in a rare gene editing IPOThe startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.BioPharma Dive · 5d ago↗ source
- Scribe records upsized $129M IPO to bankroll lipid-lowering genetic medsIn vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.